For the year ending 2025-12-31, MLYS had $58,830K increase in cash & cash equivalents over the period. -$142,431K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -154,651 |
| Accretion of discount on held-to-maturity securities | 9,879 |
| Stock-based compensation | 19,324 |
| Depreciation and amortization | 59 |
| Accrued interest receivable | 166 |
| Prepaid, other current assets, and other assets | -2,470 |
| Accounts payable and accrued liabilities | 427 |
| Net cash used in operating activities | -142,416 |
| Purchases of marketable securities | 814,738 |
| Maturities of marketable securities | 425,000 |
| Purchases of property and equipment | 15 |
| Net cash provided by (used in) investing activities | -389,753 |
| Proceeds from issuance of common stock public offering, net of offering costs and proceeds from issuance of common stock pursuant to atm agreement, net of issuance costs-Public Offering September2025 | 269,883 |
| Proceeds from issuance of common stock public offering, net of offering costs and proceeds from issuance of common stock pursuant to atm agreement, net of issuance costs-Public Offering March2025 | 188,880 |
| Proceeds from issuance of common stock public offering, net of offering costs and proceeds from issuance of common stock pursuant to atm agreement, net of issuance costs-At The Market | 119,598 |
| Proceeds from stock option exercises | 12,786 |
| Proceeds from issuance of common stock for cash under employee stock purchase plan | 243 |
| Payment of shelf offering costs | 391 |
| Proceeds from issuance of common stock and pre-funded warrants in a private placement offering, net of offering costs | 0 |
| Net cash provided by financing activities | 590,999 |
| Net increase in cash and cash equivalents | 58,830 |
| Cash and cash equivalents - beginning | 114,091 |
| Cash and cash equivalents - ending | 172,921 |
Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics, Inc. (MLYS)